Enveric Biosciences Q1 net loss narrows as funding rises

Enveric Biosciences, Inc.

Enveric Biosciences, Inc.

ENVB

0.00


Overview

  • US biotechnology firm's Q1 net loss narrowed yr/yr, with loss per share at $1.08

  • Company raised $2.8 mln in gross proceeds during Q1 and added further funding post-quarter

  • Enveric advanced EB-003 preclinical studies and strengthened its intellectual property portfolio


Outlook

  • Company expects cash balance to fund operations into the first qtr of fiscal yr 2027

  • Enveric plans to submit IND for EB-003 and begin first-in-human clinical trials

  • Company sees supportive policy environment for innovation in mental health therapies


Result Drivers

  • PIPELINE INVESTMENT - Ongoing preclinical development of lead candidate EB-003 drove spending in Q1

  • INTELLECTUAL PROPERTY - Co strengthened its IP portfolio with new patent issuances and resolution of a post-grant review petition

  • CAPITAL RAISES - Gross proceeds of $2.8 mln raised in Q1 and further funds secured post-quarter to support operations


Company press release: ID:nBw4gQHPja


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

-$1.08

Q1 Net Income

-$1.60 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.